| 产品名称： | Serratia marcescens Bizio |
|---|---|
| 商品货号： | TS202851 |
| Strain Designations： | 3G |
| Application： | Enteric Research |
| Isolation： | Human blood, Belgium |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | no |
| Antibiotic Resistance： | Depositors claim multidrug resistance to amikacin, aztreonam, carbenicillin, cefoperazone, cefotaxime, cefoxitin, chloramphenicol, ciprofloxacin, mezlocillin, piperacillin, tetracycline, and tobramycin (see reference). ATCC could confirm antibiotic resistance only to cefoxitin and tobramycin. |
| Comments： | Depositors claim multidrug resistance to amikacin, aztreonam, carbenicillin, cefoperazone, cefotaxime, cefoxitin, chloramphenicol, ciprofloxacin, mezlocillin, piperacillin, tetracycline, and tobramycin (see reference). ATCC could confirm antibiotic resistance only to cefoxitin and tobramycin. |
| Medium： | ATCC® Medium 1522: Trypticase soy medium (ATCC medium 18) with 8 mcg/ml of tobramycin |
| Growth Conditions： | Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor： | CC Sanders |
| Chain of Custody： | ATCC |
| References： | Sanders CC, Watanakunakorn C. Emergence of resistance to þ-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. J. Infect. Dis. 153: 617-619, 1986. PubMed: 3512733 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Serratia marcescens Bizio |
|---|---|
| 商品货号： | TS202851 |
| Strain Designations： | 3G |
| Application： | Enteric Research |
| Isolation： | Human blood, Belgium |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | no |
| Antibiotic Resistance： | Depositors claim multidrug resistance to amikacin, aztreonam, carbenicillin, cefoperazone, cefotaxime, cefoxitin, chloramphenicol, ciprofloxacin, mezlocillin, piperacillin, tetracycline, and tobramycin (see reference). ATCC could confirm antibiotic resistance only to cefoxitin and tobramycin. |
| Comments： | Depositors claim multidrug resistance to amikacin, aztreonam, carbenicillin, cefoperazone, cefotaxime, cefoxitin, chloramphenicol, ciprofloxacin, mezlocillin, piperacillin, tetracycline, and tobramycin (see reference). ATCC could confirm antibiotic resistance only to cefoxitin and tobramycin. |
| Medium： | ATCC® Medium 1522: Trypticase soy medium (ATCC medium 18) with 8 mcg/ml of tobramycin |
| Growth Conditions： | Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor： | CC Sanders |
| Chain of Custody： | ATCC |
| References： | Sanders CC, Watanakunakorn C. Emergence of resistance to þ-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. J. Infect. Dis. 153: 617-619, 1986. PubMed: 3512733 |
